TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.

This study tests a three-part treatment for newly diagnosed glioblastoma — a serious type of brain tumor. After surgery and standard radiation plus chemotherapy, patients would receive electrical field therapy (a wearable device that disrupts cancer cell growth), an ongoing chemotherapy drug called temozolomide, and an immunotherapy drug called tislelizumab. **You may be eligible if...** - You are 18 or older and have been diagnosed with glioblastoma (confirmed by biopsy) that sits above the brainstem - Your brain tumor does not have the IDH mutation (wild-type) - You have already completed surgery and radiation with temozolomide, and are now planning maintenance chemotherapy - You are in reasonably good physical condition (Karnofsky score ≥70) with an expected survival of at least 3 months **You may NOT be eligible if...** - Your cancer progressed early during radiation and chemotherapy - You have cancer that has spread to the fluid around the brain and spinal cord - You have had other cancer treatment in the past 5 years (with some exceptions) - You have an implanted device like a pacemaker, deep brain stimulator, or cardiac defibrillator - You are pregnant, breastfeeding, or trying to become pregnant - You have skin wounds, ulcers, or infections where the device electrodes would be placed Talk to your doctor to see if this trial is right for you.